✦ LIBER ✦

Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS)

✍ Scribed by Amanda Cashen; Mark Juckett; Alcee Jumonville; Mark Litzow; P. J. Flynn; John Eckardt; Betsy LaPlant; Kristina Laumann; Charles Erlichman; John DiPersio

Publisher: Springer
Year: 2011
Tongue: English
Weight: 131 KB
Volume: 91
Category: Article
ISSN: 0939-5555
DOI: 10.1007/s00277-011-1240-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Activity of the histone deacetylase inhi

Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer

✍ Xiaozhong Qian; Gulshan Ara; Evan Mills; William J. LaRochelle; Henri S. Lichens 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 751 KB

## Abstract Histone deacetylase inhibitors (HDACi) represent a promising new class of anticancer agents. In the current investigation, we examined the activity of the HDACi belinostat in preclinical models of prostate cancer. __In vitro__ proliferation assays demonstrated that belinostat potently i

Pharmacokinetic and pharmacodynamic prop

Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101)

✍ N. L. Steele; J. A. Plumb; L. Vidal; J. Tjørnelund; P. Knoblauch; P. Buhl-Jensen 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 298 KB

Plasma and cerebrospinal fluid pharmacok

Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates

✍ Katherine E. Warren; Cindy McCully; Henrik Dvinge; Jette Tjørnelund; Maxwell Seh 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 237 KB

Phase II study of the histone deacetylas

Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome

✍ Sophie Dimicoli; Elias Jabbour; Gautam Borthakur; Tapan Kadia; Zeev Estrov; Hui 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 850 KB

Phase 2 trial of the histone deacetylase

Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma

✍ Ruben Niesvizky; Scott Ely; Tomer Mark; Sangeeta Aggarwal; Janice L Gabrilove; J 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 355 KB 👁 2 views

Azacitidine for treatment of patients wi

Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group

✍ Katharina Götze; Uwe Platzbecker; Aristoteles Giagounidis; Detlef Haase; Michael 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 175 KB